Zobrazeno 1 - 9
of 9
pro vyhledávání: '"Mary F McMullin"'
Autor:
Thomas G Smith, Jerome T Brooks, George M Balanos, Terence R Lappin, D Mark Layton, Dawn L Leedham, Chun Liu, Patrick H Maxwell, Mary F McMullin, Christopher J McNamara, Melanie J Percy, Christopher W Pugh, Peter J Ratcliffe, Nick P Talbot, Marilyn Treacy, Peter A Robbins
Publikováno v:
PLoS Medicine, Vol 3, Iss 7, p e290 (2006)
BackgroundThe von Hippel-Lindau tumour suppressor protein-hypoxia-inducible factor (VHL-HIF) pathway has attracted widespread medical interest as a transcriptional system controlling cellular responses to hypoxia, yet insights into its role in system
Externí odkaz:
https://doaj.org/article/52c8f8c7977a47c5b133c24f88912721
Autor:
Zijian Fang, Giuditta Corbizi Fattori, Thomas McKerrell, Rebecca H. Boucher, Aimee Jackson, Rachel S. Fletcher, Dorian Forte, Jose-Ezequiel Martin, Sonia Fox, James Roberts, Rachel Glover, Erica Harris, Hannah R. Bridges, Luigi Grassi, Alba Rodriguez-Meira, Adam J. Mead, Steven Knapper, Joanne Ewing, Nauman M. Butt, Manish Jain, Sebastian Francis, Fiona J. Clark, Jason Coppell, Mary F. McMullin, Frances Wadelin, Srinivasan Narayanan, Dragana Milojkovic, Mark W. Drummond, Mallika Sekhar, Hesham ElDaly, Judy Hirst, Maike Paramor, E. Joanna Baxter, Anna L. Godfrey, Claire N. Harrison, Simón Méndez-Ferrer
Publikováno v:
Nature Communications, Vol 14, Iss 1, Pp 1-21 (2023)
Abstract Current therapies for myeloproliferative neoplasms (MPNs) improve symptoms but have limited effect on tumor size. In preclinical studies, tamoxifen restored normal apoptosis in mutated hematopoietic stem/progenitor cells (HSPCs). TAMARIN Pha
Externí odkaz:
https://doaj.org/article/16a1a95232b2462f94a84a299c0e1020
Autor:
Ruben A. Mesa, Stacie Hudgens, Lysbeth Floden, Claire N. Harrison, Jeanne Palmer, Vikas Gupta, Donal P. McLornan, Mary F. McMullin, Jean‐Jaques Kiladjian, Lynda Foltz, Uwe Platzbecker, M. Laura Fox, Adam J. Mead, David M. Ross, Stephen T. Oh, Andrew Perkins, Michael F. Leahy, Samineh Deheshi, Rafe Donahue, Barbara J. Klencke, Srdan Verstovsek
Publikováno v:
Cancer Medicine, Vol 12, Iss 9, Pp 10612-10624 (2023)
Abstract Background Myelofibrosis (MF)‐associated constitutional symptoms can severely impact health‐related quality of life. Clinical trials in MF traditionally measure symptom response to treatment as a landmark endpoint of total symptom score
Externí odkaz:
https://doaj.org/article/e6eb999637b34b008d60fd675f19d445
Autor:
Ruben A. Mesa, Stacie Hudgens, Lysbeth Floden, Claire N. Harrison, Jeanne Palmer, Vikas Gupta, Donal P. McLornan, Mary F. McMullin, Jean‐Jaques Kiladjian, Lynda Foltz, Uwe Platzbecker, M. Laura Fox, Adam J. Mead, David M. Ross, Stephen T. Oh, Andrew Perkins, Michael F. Leahy, Samineh Deheshi, Rafe Donahue, Barbara J. Klencke, Srdan Verstovsek
Publikováno v:
Mesa, R A, Hudgens, S, Floden, L, Harrison, C N, Palmer, J, Gupta, V, McLornan, D P, McMullin, M F, Kiladjian, J-J, Foltz, L, Platzbecker, U, Fox, M L, Mead, A J, Ross, D M, Oh, S T, Perkins, A, Leahy, M F, Deheshi, S, Donahue, R, Klencke, B J & Verstovsek, S 2023, ' Symptomatic benefit of momelotinib in patients with myelofibrosis: results from the SIMPLIFY phase III studies ', Cancer Medicine . https://doi.org/10.1002/cam4.5799
Scientia
Scientia
Momelotinib; Myelofibrosis; Patient-reported outcomes Momelotinib; Mielofibrosi; Resultats informats pel pacient Momelotinib; Mielofibrosis; Resultados informados por el paciente Background Myelofibrosis (MF)-associated constitutional symptoms can se
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::bcfbb9cc40d930868fce1d2a253b5f47
https://doi.org/10.1002/cam4.5799
https://doi.org/10.1002/cam4.5799
Autor:
Francis Mussai, Carmela De Santo, Paul Cheng, Ian F. Thomas, Cono Ariti, Laura Upton, Ugo Scarpa, Victoria Stavrou, Mia Sydenham, Alan K. Burnett, Steven K. Knapper, Priyanka Mehta, Mary F. McMullin, Mhairi Copland, Nigel H. Russell, Mike Dennis
Publikováno v:
British Journal of Haematology. 200:573-578
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::4d46208595d103723549ab46f86de175
https://doi.org/10.1111/bjh.18560
https://doi.org/10.1111/bjh.18560
Autor:
Francis, Mussai, Carmela, De Santo, Paul, Cheng, Ian F, Thomas, Cono, Ariti, Laura, Upton, Ugo, Scarpa, Victoria, Stavrou, Mia, Sydenham, Alan K, Burnett, Steven K, Knapper, Priyanka, Mehta, Mary F, McMullin, Mhairi, Copland, Nigel H, Russell, Mike, Dennis
Publikováno v:
British journal of haematologyREFERENCES.
The survival of acute myeloid leukaemia (AML) patients aged over 60 has been suboptimal historically, whether they are treated using hypomethylating agents, low-dose cytarabine (LDAC) or venetoclax-based regimens. Progress is being made, however, for
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::7ea80bffb99fd227fedf0697f296a221
https://pubmed.ncbi.nlm.nih.gov/36413792
https://pubmed.ncbi.nlm.nih.gov/36413792
Autor:
Alberto Alvarez-Larrán, Arturo Pereira, Paola Guglielmelli, Juan Carlos Hernández-Boluda, Eduardo Arellano-Rodrigo, Francisca Ferrer-Marín, Alimam Samah, Martin Griesshammer, Ana Kerguelen, Bjorn Andreasson, Carmen Burgaleta, Jiri Schwarz, Valentín García-Gutiérrez, Rosa Ayala, Pere Barba, María Teresa Gómez-Casares, Chiara Paoli, Beatrice Drexler, Sonja Zweegman, Mary F. McMullin, Jan Samuelsson, Claire Harrison, Francisco Cervantes, Alessandro M. Vannucchi, Carlos Besses
Publikováno v:
Haematologica, Vol 101, Iss 8 (2016)
The role of antiplatelet therapy as primary prophylaxis of thrombosis in low-risk essential thrombocythemia has not been studied in randomized clinical trials. We assessed the benefit/risk of low-dose aspirin in 433 patients with low-risk essential t
Externí odkaz:
https://doaj.org/article/4d3a0a6c203546489418048bfb501409
Autor:
Lesley A, Anderson, Glen, James, Andrew S, Duncombe, Ruben, Mesa, Robyn, Scherber, Amylou C, Dueck, Frank, de Vocht, Mike, Clarke, Mary F, McMullin
Publikováno v:
American journal of hematology. 90(10)
The myeloproliferative neoplasms (MPN) including polycythaemia vera (PV), essential thrombocythaemia and primary myelofibrosis (PMF) are rare diseases contributing to significant morbidity. Symptom management is a prime treatment objective but curren
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::8253bfe7950131956fab99dbe85ac93f
https://pubmed.ncbi.nlm.nih.gov/26113113
https://pubmed.ncbi.nlm.nih.gov/26113113
Autor:
Alan K. Burnett, Donald Milligan, Archie G. Prentice, Anthony H. Goldstone, Mary F. McMullin, Robert K. Hills, Keith Wheatley
Publikováno v:
Cancer (0008543X); Mar2007, Vol. 109 Issue 6, p1114-1124, 11p